Vol. 5 No. 1 (2025)
Reimbursement Reviews

Secukinumab (Cosentyx)

decorative image of the issue cover

Published January 17, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Secukinumab (Cosentyx) 75 mg/0.5 mL, 150 mg/1 mL, and 300 mg/2 mL solution for injection and 150 mg powder for solution for injection.
  • Indication: For the treatment of adult patients with moderate to severe hidradenitis suppurativa (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy.